Management of decompensated cirrhosis

Authors: Dina Mansour and Stuart McPherson

Decompensated cirrhosis is a common reason for admission to the acute medical unit, and such patients typically have complex medical needs and are at high risk of in-hospital death. It is therefore vital that these patients receive appropriate investigations and management as early as possible in their patient journey. Typical presenting clinical features include jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome or variceal haemorrhage. A careful history, examination and investigations can help identify the precipitating cause (infections, gastrointestinal bleeding, high alcohol intake / alcohol-related hepatitis or drug-induced liver injury), so appropriate treatment can be given. A ‘care bundle’ that has been endorsed by the British Society of Gastroenterology is available to help guide the management of patients with decompensated cirrhosis for the first 24 hours and ensure all aspects are addressed. Specific management of complications, such as infections, gastrointestinal bleeding, hepatic encephalopathy and hepatorenal syndrome, are discussed.

KEYWORDS: Alcohol-related liver disease, ascites, cirrhosis, hepatic encephalopathy, hepatitis, hepatorenal syndrome, infections

Introduction

Decompensated cirrhosis is a frequent reason for admission to the acute medical unit, and such patients typically have complex medical needs that can lead to a prolonged hospital stay and a significant risk of an in-hospital death (10–20%). It is therefore vital that these patients receive the appropriate investigations and treatment as early as possible in their patient journey. The aim of this review is to provide an overview of the management of decompensated cirrhosis for non-specialists.

Decompensated cirrhosis is defined as an acute deterioration in liver function in a patient with cirrhosis and is characterised by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome or variceal haemorrhage. Common precipitants of hepatic decompensation include infections, gastrointestinal (GI) bleeding, high alcohol intake / alcohol-related hepatitis or drug-induced liver injury although no specific cause is found in approximately 50% of cases. It is important to try to determine the underlying cause of hepatic decompensation through a careful history, examination and investigations so appropriate treatment can be given.

Assessment of a patient with decompensated cirrhosis

Initial assessment of a patient with decompensated cirrhosis in the acute setting can be performed using the ABC (airway, breathing, circulation) approach.

Airway

The airway can be compromised in patients with severe hepatic encephalopathy where their conscious level is reduced (grade 3 or 4) or in those who present with large volume haematemesis. In these circumstances, early intubation and ventilation must be considered.

Breathing

Breathing is commonly compromised in patients with cirrhosis. Common causes of impaired breathing in cirrhotic patients include pneumonia (including aspiration pneumonia), pulmonary oedema (due to alcohol-related, ischaemic or cirrhotic cardiomyopathy), hepatic hydrothorax and gross ascites causing splinting of the diaphragm. Breathlessness can also be due to pulmonary complications of portal hypertension, namely portopulmonary hypertension (defined as pulmonary artery pressure >25 mmHg in a patient with portal hypertension and no other cause) and hepatopulmonary syndrome (HPS; triad of liver dysfunction, intrapulmonary vasodilation and arterial oxygenation defect). HPS is characterised by platypnoea and orthodeoxia (dyspnoea and hypoxia worse in the upright position and improved by lying flat) and can be diagnosed on bubble echocardiography. Both portopulmonary hypertension and HPS improve following liver transplant.

Breathing should be assessed by respiratory rate, oxygen saturations and auscultation of the chest. In the context of tense ascites, early paracentesis can improve respiratory function.

Circulation

Hypotension and tachycardia can occur as a result of sepsis, hypovolaemia/overdissuresis and GI bleeding. Tachycardia may not be present in subjects with significant hypovolaemia who are on beta-blockers. While it is important to identify and ameliorate the cause, the initial focus should be on adequate resuscitation. Hypovolaemic or shocked patients should be fluid resuscitated in...
Decompensated cirrhosis

the same manner as non-cirrhotic patients with an intravenous crystalloid, according to pulse and blood pressure, aiming for a mean arterial pressure >80 mmHg. Human albumin solution (5%) is an alternative volume expander, but is not always immediately available in an emergency situation. Those with evidence of GI haemorrhage should be managed as described below.

Hydration status can be difficult to assess in cirrhotic patients. Some patients appear peripherally overloaded because of hypoalbuminaemia, but are intravascularly deplete. Patients also tend to be vasodilated, which makes them chronically hypotensive – chasing a ‘normal’ blood pressure can push them into fluid overload. A careful assessment of pulse, blood pressure, jugular venous pulse and mucous membranes is needed, in addition to hourly fluid balance (aiming for urine output of >0.5 mL/kg) and daily body weight measurement.

Disability

Documentation of the patient’s Glasgow Coma Scale score, grade of encephalopathy (Table 1) and signs of alcohol withdrawal is mandatory. In addition, the temperature (sepsis can cause hyper- or hypothermia) and blood glucose (liver failure can cause hypoglycaemia) should be recorded. Asterixis is an important sign, identifying patients with grade 2 encephalopathy.

Exposure

A complete physical examination of the patient should be undertaken to look for the underlying cause of hepatic decompensation. Abdominal examination may reveal ascites, and any abdominal tenderness could suggest spontaneous bacterial peritonitis (SBP). Rectal examination is important to exclude melaena. Important things not to miss are possible foci of infection, such as cellulitis or septic arthritis. A neurological examination should be performed, as subdural haematoma or a cerebral vascular accident with dysphasia can be misdiagnosed as encephalopathy. There may also be signs of chronic liver disease (muscle atrophy, spider naevi, palmer erythema, caput medusa and gynaecomastia).

A full medical history and investigations should be conducted as shown in Box 1.

| Grade of encephalopathy | Symptoms/signs |
|-------------------------|----------------|
| Grade 1                 | Trivial lack of awareness, euphoria or anxiety, shortened attention span, impaired performance of addition or subtraction |
| Grade 2                 | Lethargy or apathy, minimal disorientation for time or place, subtle personality change, inappropriate behaviour, asterixis |
| Grade 3                 | Somnolence to semi-stupor, but responsive to verbal stimuli, confusion, gross disorientation |
| Grade 4                 | Coma |

Table 1. West-Haven criteria for grading hepatic encephalopathy

Management of decompensated cirrhosis

Decompensated cirrhosis is a complex disorder affecting multiple systems and therefore requires a systematic approach to its management. A ‘care bundle’, endorsed by the British Society of Gastroenterology, is available to help guide the management of patients with decompensated cirrhosis for the first 24 hours.

A multicentre review in three English hospitals found that use of this care bundle improved all aspects of care and can help ensure patients with decompensated cirrhosis receive optimum management early in their hospital admission.

Infections

As patients with cirrhosis are effectively immunosuppressed, infections are one of their most common reasons for hepatic decompensation. The most common infections in patients with cirrhosis are SBP, urinary tract infections, pneumonia and cellulitis. Gram-negative bacteria (particularly Escherichia coli) and Gram-positive cocci are the most common pathogens. SBP is infection in the ascitic fluid in the absence of a surgical cause. Symptoms include fever, abdominal pain, hypotension and encephalopathy, but one-third of patients are asymptomatic. Therefore, any patient admitted with clinically detectable ascites and decompensated liver disease should have a diagnostic ascitic tap performed on admission. SBP is confirmed by finding an ascitic fluid polymorphonuclear cell count of >250/mm³ (0.25×10⁹/L).
or encephalopathy should be intubated for the procedure to
be performed. If haemostasis cannot be achieved then balloon tamponade with a Stengsaken-Blackmore
tube, or equivalent, should be used.17 Transjugular intrahepatic portosystemic shunt should be considered if haemostasis
cannot be achieved endoscopically or the patient rebleeds.13 UK
guidelines advise a combination of non-selective beta-blocker
(such as carvedilol 6.25–12.5 mg daily) in addition to variceal band
ligation for secondary prophylaxis of variceal bleeds following

dischARGE.13

Hepatic encephalopathy
Hepatic encephalopathy refers to the range of neurological
abnormalities seen in patients with cirrhosis. The exact
mechanism is not known, but is thought to be due to excess
circulating toxins crossing the blood-brain barrier, including
ammonia and glutamine. Hepatic encephalopathy is graded from
1 to 4 (Table 1).17 A diagnosis of hepatic encephalopathy is made
on the basis of history and examination. The presence of asterixis
diagnostic of hepatic encephalopathy. Other causes of mental
state changes should be excluded, and consider a computerised
tomography head to rule out pathology, such as subdural
haematoma.12 Serum ammonia levels do not aid the diagnosis of
hepatic encephalopathy in cirrhotic patients presenting acutely.18
Precipitants of hepatic encephalopathy include infection,
constipation, electrolyte disturbance (particularly hypokalaemia),
sedative drugs and GI bleeding. The mainstay of treatment of
acute hepatic encephalopathy involves correcting the precipitant
and encouraging elimination of toxins using lactulose (orally or
via nasogastric tube, titrated to bowel frequency, aiming for 2–3
soft stools per day) and enemas, if required. The non-absorbable
antibiotic, rifaximin (550 mg twice per day), can be added if the
patient fails to respond to laxatives.17

Alcohol-related hepatitis
Alcohol-related hepatitis is a syndrome of rapid onset jaundice
c(3 months), liver failure and systemic inflammation associated
with prolonged heavy alcohol consumption. Typical clinical
findings in patients with alcohol-related hepatitis are tender
hepatomegaly, fever, ascites or encephalopathy. Blood tests show
hyperbilirubinaemia, coagulopathy, neutrophilia and a modest
transaminis (2–6 times the upper limit of normal) with an
asparate aminotransferase / alanine aminotransferase ratio >2. It
can be difficult to differentiate alcohol-related hepatitis from other
causes of hepatic decompensation, so other causes, such as sepsis,
need to be excluded.19

Long-term abstinence from alcohol is the most important
prognostic factor in patients with alcohol-related hepatitis and
every effort should be made to help patients achieve this. Specific
treatment of alcohol-related hepatitis should be considered if the
patient’s Maddrey discriminant function, a widely used prognostic
score for alcohol-related hepatitis, is >32, as this predicts an
increased risk of early mortality.

Although the treatment for alcohol-related hepatitis remains
contentious, prednisolone 40 mg for 28 days has the best
evidence.20,21 The STOPAH (Steroids or Pentoxifylline for Alcoholic
Hepatitis) trial, which was published in 2015, tried to definitively
determine whether prednisolone was effective in severe alcohol-
related hepatitis.20 This trial enrolled more than 1,000 patients

Dina Mansour and Stuart McPherson

© Royal College of Physicians 2018. All rights reserved.
Decompensated cirrhosis

with a clinical diagnosis of severe alcohol-related hepatitis at multiple sites across the UK and randomised them to 28 days treatment with placebo, prednisolone 40 mg, pentoxifylline 400 mg or prednisolone and pentoxifylline. Overall, there was a trend towards a reduction in 28-day mortality in those treated with prednisolone compared with placebo (odds ratio [OR] 0.72, CI 0.52–1.01, p=0.06), but pentoxifylline had no effect. Statistical analysis revealed subtle differences in the clinical characteristics between treatment groups in this study. Following multivariate analysis, correcting for baseline factors associated with survival, treatment with prednisolone was associated with improved 28-day survival compared with placebo (OR 0.61, CI 0.41–0.91, p=0.02). Unfortunately, there was no significant difference between the groups at 3 months or 1 year follow-up (overall: 54% survival at 1 year). There was a worryingly high rate of alcohol relapse (60%), which may have contributed to the poor 1-year survival rates.

When the results of the STOPAH trial were included in a meta-analysis, treatment with corticosteroids for alcohol-related hepatitis was associated with a significant reduction in short-term mortality. Prednisolone may therefore have a modest impact on short-term mortality in severe alcohol-related hepatitis, but pentoxifylline is ineffective.

The main risk from using steroids in patients with alcohol-related hepatitis is sepsis, so it is important to exclude or treat sepsis before commencing steroids. For patients who start prednisolone, consider assessing their response at 7 days using the Lille score as 40% have no significant improvement in liver function (Lille score of ≥0.45) and have an increased risk of sepsis if steroids are continued beyond 7 days. Given the lack of highly effective treatments for alcohol-related hepatitis, a number of compounds are now undergoing clinical trials (Table 2).

AKI, hepatorenal syndrome and hyponatraemia

AKI is common in patients with decompensated cirrhosis, with approximately 20% of patients affected. It can occur secondary to pre-renal AKI (45%), acute tubular necrosis / primary renal disease (including nephrotoxic drugs) (32%), or hepatorenal syndrome (23%) and is often multifactorial. AKI in cirrhotic patients is defined as the increase in creatinine of >26 μmol/L within 48 hours and/or ≥50% from baseline over 7 days.

Table 2. New and future treatments for alcohol-related hepatitis

| Mechanism of action | Method | Evidence | Current trials a |
|---------------------|--------|----------|-----------------|
| Inhibition of oxidative stress | N-acetyl cysteine (NAC) + corticosteroids | NAC (IV 5 days) + corticosteroids significantly reduced mortality at 1 month vs steroids alone | Current trial of intravenous NAC + corticosteroids vs corticosteroids alone NCT02971306 |
| | S-adenosylmethionine | Promising in small studies only, trials required | |
| Blockade of apoptosis | ASK-1 (apoptosis signal-regulating kinase-1) inhibitor GS-4997/selonsertib | | Current trial ASK-1 inhibitor +corticosteroids NCT02854631 |
| Reducing inflammation | Anti-tumour necrosis factor alpha | Increased mortality in clinical trials | |
| Bile acids | Obeticholic acid (Farnesoid R receptor [FXR] analogue) | In mice models cholic acid stimulates liver growth, response lost in FXR-/- mice | |
| Regeneration | Granulocyte colony stimulating factor (GCSF) | Improved survival vs placebo in pilot trial | Current trials of GCSF alone, in combination with NAC, or in null/partial responders to corticosteroid NCT026555510 |
| | Recombinant human IL-22, F-652 | Cytokine IL-22 induces liver regeneration | Current trial (TREAT 008), NCT02335632 |
| | Stem cell transplant | No survival benefit / improvement in liver function in randomised controlled trial | |
| Modulation of gut microbiota | Probiotics | | Current trial NCT02335632 |
| | Rifaximin | | NCT02485106 NCT02458079 |
| | Faecal transplant | | |
| Transplant | Early salvage liver transplant | Initial trial improved survival in patients with alcohol-related hepatitis not responding to steroids (77% vs 25% matched controls) | Current trial NCT01756794 |
| Prophylactic antibiotics | Amoxicillin/co-amoxiclav | | Current trial NCT02281929 |

Trial details can be found at ClinicalTrials.gov

© Royal College of Physicians 2018. All rights reserved.
Initial treatment of AKI in cirrhotic patients is correction of hypovolaemia with intravenous fluid. Human albumin solution (1 g/kg for 2 days; 5% albumin if hypovolaemic or 20% if euvoelaemic) is recommended by international guidelines. Large volumes of 0.9% saline or 5% dextrose should be avoided as this can promote accumulation of ascites (saline) or hyponatraemia (dextrose). Diuretics, nephrotoxins and vasodilators should be suspended. Other intrinsic causes of renal dysfunction should be excluded. If there is no significant improvement in renal function after 48 hours, hepatorenal syndrome is likely, so consider adding terlipressin 0.5–1 mg four times per day (titrating up to 12 mg/day maximum), in combination with 20–40 g albumin per day.

Hyponatraemia is also common in decompensated cirrhosis and is frequently multifactorial (diuretics, alcohol consumption, portal hypertension, proton pump inhibitors, intravenous dextrose etc.). Suspend any potential precipitating drugs. Treatment depends on fluid status, with hypovolaemic hyponatraemia being more common than hypervoelaemia. For patients with persistent hyponatraemia despite cessation of diuretics, intravenous albumin can improve the serum sodium levels. Fluid restriction should be reserved for patients with severe hyponatraemia (<120–5 mmol/L) who are euvoelaemic or hypovolaemic with normal renal function. Vaptans (vasopressin receptor agonists such as tolvaptan) have been shown to improve hyponatraemia and ascites in patients with cirrhosis, but do not effect survival and carry a risk of hepatotoxicity, and so currently they are not recommended. Small studies have suggested a role for midodrine (a vasopressor) and octreotide in treatment of cirrhotic patients with hyponatraemia and ascites; however, these findings need to be confirmed. Whichever method is used, it is important to correct the sodium slowly (<10 mmol/24 hours) to avoid the risk of precipitating central pontine myelinolysis.

Nutrition

Addressing the patient’s nutritional needs is very important in decompensated liver disease, as sarcopenia is highly prevalent. All patients should have a nutritional assessment, food chart and, if required, oral/nasogastric nutritional supplements aiming to provide a total energy intake of about 35–40 kcal/kg daily. Refeeding syndrome is a common complication, so phosphate, potassium and magnesium should be monitored daily, and electrolytes replaced orally or intravenously as appropriate. Pabrinex (intravenous thiamine) should be prescribed if there is evidence of inadequate nutrition, or in patients who consume excessive alcohol, to reduce the risk of Wernicke’s encephalopathy.

Escalation of care / end-of-life care

For cirrhotic patients who fail to respond to initial management or deteriorate, consider escalation of care to a high dependency / intensive care environment to optimise their treatment. Outcomes from the intensive care unit are reasonably good (overall >50% survival to hospital discharge), particularly for acutely reversible complications, such as a GI bleed or encephalopathy. It is important to regularly review progress of patients to avoid prolonged futile admissions. Escalation or palliative care plans should be clearly documented by the specialist teams to avoid difficult decisions for on-call teams.

Conclusions

 Decompensated cirrhosis is a common disorder presenting to acute medical units and has high mortality. A systematic approach, with the aid of a care bundle, can ensure patients receive appropriate management of their complications.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1 Moreau R, Jalan R, Gines P et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1626–37.
2 Angeli P, Gines P, Wong F et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015;62:968–74.
3 Gines P, Fernandez J, Durand F, Saliba F. Management of critically-ill cirrhotic patients. J Hepatol 2012;56(Suppl 1):S13–26.
4 Ellul MA, Ghoklar SA, Cross TJ. Hepatic encephalopathy due to liver cirrhosis. BMJ 2015;351:h4187.
5 McPherson S, Dyson J, Austin A, Hudson M. Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis-the first 24h. Frontline Gastroenterol 2016;7:16–23.
6 British Sociert of Gastroenterology. BASL decompensated cirrhosis care bundle – first 24 hours. London: BSG. www.bsg.org.uk/care-bundles/care-bundles-general/decompensated-cirrhosis-care-bundle-first-24-hours.html [Accessed 8 August 2017].
7 Dyson JK, Rajaee Kh P, Wetten A et al. Implementation of a ‘care bundle’ improves the management of patients admitted to hospital with decompensated cirrhosis. Aliment Pharmacol Ther 2016;44:1030–8.
8 Bunchhittakul C, Chamosrookul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol 2016;8:307–21.
9 Sop T, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403–9.
10 Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49:2087–107.
11 Juniper M, Smith N, Kelly K, Mason M. Measuring the units: a review of patients who died with alcohol-related liver disease. London: National Confidential Enquiry into Patient Outcome and Death, 2013.
12 Jainta V, Rehal S, Logan R et al. Acute variceal haemorrhage in the United Kingdom: patient characteristics, management and outcomes in a nationwide audit. Dig Liver Dis 2014;46:419–26.
13 Tripathi D, Stanley AJ, Hayes PC et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015;64:1680–704.
14 Villanueva C, Colomo A, Bosch A et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11–21.
15 Chavez- Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FJ et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding – an updated Cochrane review. Aliment Pharmacol Ther 2011;34:509–18.
16 National Institute for Health and Care Excellence. Acute upper gastrointestinal bleeding in over 163: management. NICE clinical guideline No 141. London: NICE, 2016.
17 Leise MD, Poterucha JJ, Kamarthi PS et al. Management of Hepatic Encephalopathy in the Hospital. Mayo Clin Proc 2014;89:241–53.
Decompensated cirrhosis

18 Lockwood AH. Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis 2004;19:345-9.
19 McPherson S, Lucey MR, Moriarty KJ. Decompensated alcohol related liver disease: acute management. BMJ 2016;352:i124.
20 Thursz MR, Richardson P, Allison M et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;372:1619–28.
21 Singh S, Murad MH, Chan AK et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology 2015;148:958–70.
22 Louvet A, Wartal F, Castel H et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009;137:541–8.
23 Lantier N, Stärkel P. Treatment of severe alcoholic hepatitis: past, present and future. Eur J Clin Invest 2017;47:531–9.
24 Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064–77.
25 McCormick PA, Mistry P, Kaye G et al. Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut 1990;31:206–7.
26 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397–417.
27 Facciorusso A, Amoruso A, Neve V et al. Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis. World J Hepatol 2014;6:793–9.
28 Patel S, Nguyen-D-S, Rastogi A, Nguyen MK, Nguyen MK. Treatment of cirrhosis-associated hyponatraemia with midodrine and octreotide. Front Med 2017;4:17.
29 Rossi RE, Conte D, Massironi S. Diagnosis and treatment of nutritional deficiencies in alcoholic liver disease: overview of available evidence and open issues. Dig Liver Dis 2015;47:819–25.
30 McPhail MJ, Shawcross DL, Abeles RD et al. Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failure-Sequential Organ Failure Scoring System. Clin Gastroenterol Hepatol 2015;13:1353–60.

Address for correspondence: Dr Stuart McPherson, Liver Unit, Level 6, Freeman Hospital, Freeman Road, Newcastle upon Tyne NE7 7DN, UK.
Email: stuart.mcpherson@nuth.nhs.uk